05-Dec-2013 - Jubilant Life Sciences has received a US FDA warning letter for its manufacturing plant in Spokane, Washington State.
05-Dec-2013 - CMO Ben Venue Laboratories has asked Bank of America Merrill Lynch to try and find a buyer for its generic injectables business, Bedford Labs.
05-Dec-2013 - Hovione says demand drove acquisition of new capsule filling technology for inhalable drug products.
05-Dec-2013 - A lawsuit alleging that the US FDA unlawfully detained a batch of acetaminophen API destined for CMO Gemini Pharmaceuticals could have significant impact on the drug industry's definition of an...
04-Dec-2013 - Soon to be merged CMO DSM Pharmaceutical Products (DPP) has been contracted to provide process development for a protein allergy drug being developed by Tunitas Therapeutics.
03-Dec-2013 - Soon to merge CMO Patheon has increased solid dosage form production capacity at its site in the UK and posted an improved set of preliminary results for the financial year.
03-Dec-2013 - Unilife has agreed to supply customised drug delivery devices to Novartis in the fourth major deal inked in the last few months.
03-Dec-2013 - The US Food and Drug Administration (FDA) has approved SCM Pharma to manufacture BTG’s varicose vein treatment from its Northumberland, UK facility.
02-Dec-2013 - The US FDA has defined compounding pharmacies as ‘outsourcing facilities’ in new guidance issued days after the Drug Quality and Security Act (DQSA) became law .
02-Dec-2013 - Apotek Produktion & Laboratorier AB (APL) says manufacturing knowledge and drug delivery tech knowhow gained by its compounding business is a boon for its CMO unit.
26-Nov-2013 - Catalent says it is creating dedicated space and possibly jobs at its Missouri facility in order to service a commercial contract for Pharmacyclics’ oncology drug Imbruvica.
26-Nov-2013 - Unilife has signed a $40m long-term supply agreement with Hikma and says it is committed to becoming the world’s largest and most successful injectable drug delivery systems supplier.
26-Nov-2013 - Kemwell CEO Agneta Bergvall says drugmakers' efforts to make pharmaceutical manufacturing green are worth the cost.
25-Nov-2013 - Particle Sciences has been tasked with creating a nasal formulation of the steroid hormone progesterone that can be used to treat patients who have suffered traumatic brain injury.
21-Nov-2013 - The high cost of energy in the UK is having a negative impact on drug and chemical firms' ability to compete according to manufacturers quizzed by the Chemical Industries Association...
19-Nov-2013 - Royal DSM wants to merge its pharmaceutical products business with Patheon and has signed a deal with the latter's owner, investment group JLL Partners.
18-Nov-2013 - Catalent has cut the ribbon on its Clinical Supply facility in China just months after construction began.
18-Nov-2013 - WuXi says diversifying its client base means it is not worried about big clients like Merck & Co. restructuring R&D as the firm reports a strong Q3.
13-Nov-2013 - West says it is one step closer to bringing the Daikyo Crystal Zenith (CZ) drug delivery system to commercialisation with the completion of a first-in-man study.
12-Nov-2013 - Hospira has received a Form 483 from the US Food and Drug Administration (FDA) noting three observations at its Kansas manufacturing facility.
11-Nov-2013 - Bend Research is expanding its commercial spray-dried dispersion (SDD) manufacturing with capital from new owners Capsugel in order to offer unique integrated capabilities, the firm says.
11-Nov-2013 - Evonik has upped its capabilities in highly potent active pharmaceutical ingredients (HPAPI) citing the increased market growth of oncology drugs.
07-Nov-2013 - Remediation at troubled Rocky Mount facility will continue into 2014 Hopira says as it awaits an inspection by the US Food and Drug Administration (FDA).
07-Nov-2013 - CatScI says pharma demand for catalysis services is increasing due to a greater focus on economic sustainability as it inks a deal with SAFC for its chemical processes.
06-Nov-2013 - Persistence, endurance and a steadfast focus has led to AMRI receiving a close-out letter for its long suffering Burlington, Massachusetts facility, the company says.